Antibacterial protein CDL200 having lytic activity against Clostridioides difficile

Patent metadata

Field	Value
Publication number	US-12503494-B2
Application number	US-202117920149-A
Country	US
Kind code	B2
Filing date	Mar 31, 2021
Priority date	Apr 22, 2020
Publication date	Dec 23, 2025
Grant date	Dec 23, 2025

Abstract

The present invention relates to an antibacterial protein CDL200 with an antibacterial activity specific against Clostridioides difficile . More specifically, the present invention relates to an antibacterial protein CDL200 specific to Clostridioides difficile that may infect and cause disease in animals including humans, the antibacterial protein CDL200 being characterized by having the ability to specifically lyse the Clostridioides difficile and containing the amino acid sequence represented by SEQ ID NO: 1. In addition, the present invention relates to a pharmaceutical composition for treating an infection or disease caused by Clostridioides difficile , the composition containing the antibacterial protein CDL200 specific to Clostridioides difficile as an active ingredient.

First claim

The invention claimed is:

1 . A Clostridioides difficile -specific antibacterial protein CDL200 having specific antibacterial activity to Clostridioides difficile and comprising the amino acid sequence represented by SEQ ID NO: 1.

2 . The Clostridioides difficile -specific antibacterial protein CDL200 of claim 1 , characterized in that the antibacterial protein CDL200 comprises 160 amino acids and has a molecular weight of 17.6 kDa.

3 . A pharmaceutical composition for treating a Clostridioides difficile infection, the composition comprising the Clostridioides difficile -specific antibacterial protein CDL200 of claim 1 as an active ingredient.

4 . The pharmaceutical composition of claim 3 , wherein the composition is a food, antibiotic, disinfectant, or fungicide.

5 . A method of producing the Clostridioides difficile -specific antibacterial protein CDL200 of claim 1 using a strain produced by transforming Escherichia coli using a plasmid represented by the gene sequence of SEQ ID NO: 2.

6 . A method for treating a subject having a Clostridioides difficile infection or disease caused by Clostridioides difficile comprising administering to the subject a composition comprising Clostridioides difficile -specific antibacterial protein CDL200 having specific antibacterial activity to Clostridioides difficile and comprising the amino acid sequence represented by SEQ ID NO: 1.

7 . A method of killing a cell infected with Clostridioides difficile comprising contacting said cell with a composition comprising Clostridioides difficile -specific antibacterial protein CDL200 having specific antibacterial activity to Clostridioides difficile and comprising the amino acid sequence represented by SEQ ID NO: 1.

Assignees

• Intron Biotechnology Inc

Inventors

• Yoon Seong Jun
• Son Jee Soo
• Kim In Hwang
• Ahn Cheol
• Jun Soo Youn
• Kang Sang Hyeon

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A01N63/50

  Isolated enzymes; Isolated proteins (peptides A01N37/46) · CPC title

• A61P31/04 Primary

  Antibacterial agents · CPC title

• A23L33/17

  Amino acids, peptides or proteins · CPC title

• A61K38/16

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title